TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ROS production measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression and modulation of adhesion molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comfort and satisfaction during nebulization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of febrile patients appropriately treated for malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients negative for malaria who received an antibiotic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of P falciparum cases receiving appropriate treatment with artemisinin based combination therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete cytogenetic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of vaginal and oral sex partners
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Probability of unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: mean proportion of syllables stuttered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FACT-G score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reduction of nail thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of PVCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: impaired daily activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Informed subscale score of the decisional conflict scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ability to estimate chance of stroke and bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment choices made by participants
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of normalizing blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aorta compliance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual analogue scale (VAS) scores during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-min walk test increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MLHFQ score decrease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cardiac death, non-fatal AMI or any target vessel revascularisation (TVR)
Endpoint domain: Mortality/survival
Primary endpoint: Procedural anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antibody response to GMZ2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rates after primary vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severe maternal parenting stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neglectful behavior toward the index child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor warmth toward the index child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of VT/VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inappropriate treated episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Nonfatal complications
Endpoint domain: Adverse events/effects
Primary endpoint: alcohol screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of early apnea (0 to 30 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: day 84 ACR20 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal obstruction and rhinorrhea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: demand for analgesic drugs postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dosage of opioid analgesics requested
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Thrombolysis proportion within 4 hours 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of treatment program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new urogenital infections
Endpoint domain: Adverse events/effects
Primary endpoint: gonococcal infections
Endpoint domain: Adverse events/effects
Primary endpoint: chlamydial infections
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oxytocin ED90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for supplemental uterotonic agents
Endpoint domain: Adverse events/effects
Primary endpoint: Weight change after weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical improvement of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histological improvement of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cosmetic acceptability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ECG evidence of perioperative myocardial infarction
Endpoint domain: Adverse events/effects
Primary endpoint: CTnI evidence of perioperative myocardial infarction
Endpoint domain: Adverse events/effects
Primary endpoint: Need for prostaglandin administration
Endpoint domain: Adverse events/effects
Primary endpoint: PLMS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained remission of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median daily dose of prednisone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic contractile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of time required for repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental assessment of child's pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TRYCATs indolelactic acid, kynurenine, kynurenic acid, 3‐hydroxykynurenine, and quinolinic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3‐hydroxykynurenine to kynurenic acid ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CAR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 6-month cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adult arteriolar diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Adult arteriolar tortuosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: exercise efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative decline in nominal speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amount of residual bone graft material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bacterial clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of antibiotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily weight increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for NTD-affected pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TNA GMTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local and systemic vaccine-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: short physical performance exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mSASSS progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of block before epidural supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of death and dying
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Staff self-reported perceptions of capability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral compliance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in OSATS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in BOSATS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bipolar voltage attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: catheter stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of prostate cancer diagnosed following elevated PSA or abnormal DRE
Endpoint domain: Mortality/survival
Primary endpoint: Risk of prostate cancer diagnosed without a biopsy prompt
Endpoint domain: Mortality/survival
Primary endpoint: Change in herniation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 and CD8 counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HRQL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: adipose tissue reduction in calf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ET concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Severity Index (ISI) score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar ridge dimensional change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recession values comparing tissue phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rise in systolic BP from rest to peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Refractive Spherical Equivalent (MRSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-S and CGI-I score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum knee external rotation moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: vertical loading rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle inversion moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median WGTT after 120 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EI t50% delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of diarrhea/loose bowel symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean percentage change in L & B score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phototoxic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: TST conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: overall oculomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: speed of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tooth survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-step attendance
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: number of self-help activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Analgesia at rest and while coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence rates of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomotic stricture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection rate for advanced neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Instructional effectiveness of MMTB
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Instructional efficiency of MMTB
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective response to MMTB instruction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful entry during the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean change from baseline on the PANSS positive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline on the BARS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline on the DIEPSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAP usage (nightly time at pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence (percentage of night used ≥ 4 hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean 24-h median intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of microbial load in tongue and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hospital admissions during pregnancy
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clearance of darbepoetin alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of darbepoetin alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fewer disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: worsening HF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Episodes of rejection requiring antilymphocyte antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuations of study drug for treatment failures
Endpoint domain: Adverse events/effects
Primary endpoint: Peak concentrations of recAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak AP activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety concerns
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic range of phenytoin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative corneal shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of peripheral optics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of early PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of late PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective IQ
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proliferative alloresponses of PBMC and CD25(-/dim) Teff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Regulatory capacity of CD25bright T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement/healing of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relief from symptoms of regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of INR measurements within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery to fully independent function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rates of symptomatic intracerebral hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: PA behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fall risk (functional balance and strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-regulation
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: clinical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K(trans) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urinary excretion of 5alpha- and 5beta-reduced cortisol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cortisol clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lean body mass (LBM) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting heart rate (HR) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of peptic ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful application of learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Achieving designed learning plan
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Implementation of practice changes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Endoscopist satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Use of health services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Health spending
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: blood flow reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pruritus reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum concentrations of morphine and fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: PSA (Pupil Size Adjustment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSA (Spatial Sensitivity Adjustment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: High adherence to lifestyle changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weighted kappa score of the worst colposcopic finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: next-week opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MACEs
Endpoint domain: Mortality/survival
Primary endpoint: long-term survival with ipilimumab
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of ER-positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes